Immunotherapy advances in pleural mesothelioma

Our plain-English summary of Immunotherapy advances in pleural mesothelioma, by A.L. Zhang, M.L. Hsu (Therapeutic Advances in Medical Oncology, 2026).

The study

• Authors: A.L. Zhang, M.L. Hsu
• Journal: Therapeutic Advances in Medical Oncology
• Published: 2026;18:17588359261420028
• Type of article: Review
• Cited by: 1 article, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

Abstract

Mesothelioma is a rare cancer that carries a poor prognosis. This malignancy has had few therapeutic advances prior to the introduction of immune checkpoint inhibitors. Immunotherapy is now a cornerstone of first-line treatment for pleural mesothelioma and has been shown to provide clinical benefit for relapsed or refractory patients treated with prior chemotherapy. This review article will discuss key immunotherapy trials in the scientific literature, along with challenges in the application of this therapy. We will also discuss future areas of immunotherapy research in the treatment of mesothelioma.

© The Author(s), 2026.

In plain English

This article is a review, not a new study. The authors summarized published clinical trials and real-world reports of immunotherapy for pleural mesothelioma, a cancer they describe as closely associated with asbestos exposure. The review did not study asbestos exposure itself. CheckMate 743 reported a median overall survival of 18.1 months with nivolumab plus ipilimumab, compared with 14.1 months with chemotherapy, in previously untreated unresectable disease. In CONFIRM, patients whose disease had progressed after platinum-based chemotherapy had a median overall survival of 10.2 months on nivolumab, compared with 6.9 months on placebo. BEAT-meso, which added atezolizumab to chemotherapy with bevacizumab, found no statistically significant difference in survival. DENIM, which tested a dendritic cell vaccine as maintenance after chemotherapy, found no statistically significant difference in median overall survival compared with best supportive care alone. The authors wrote that there was not enough evidence to use PD-L1 status to select patients for immunotherapy. They concluded that immunotherapy has become a cornerstone in treating advanced pleural mesothelioma, particularly the chemotherapy-resistant non-epithelioid subtypes. They also concluded that better ways to predict which patients will respond are needed.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Narrative review of published immunotherapy trials and real-world reports in pleural mesothelioma; no new patient data
• Who was studied: Patients with pleural mesothelioma, mostly unresectable, as studied in published trials and real-world cohorts in the first-line and relapsed/refractory settings, plus ongoing trials including surgical patients
• Exposure: Asbestos exposure was not studied; it is mentioned only as background on the cause of the disease. The treatments reviewed were immune checkpoint inhibitors (nivolumab, ipilimumab, pembrolizumab, durvalumab, tremelimumab, atezolizumab), dendritic cell vaccination, CAR-T cell therapy and oncolytic viruses.
• Main results:
  • CheckMate 743 (reviewed trial, previously untreated unresectable mesothelioma): median overall survival was 18.1 months with nivolumab plus ipilimumab vs 14.1 months with chemotherapy (HR 0.74, 95% CI 0.60 to 0.91, p = 0.0020)
  • CONFIRM (reviewed trial, 332 patients after progression on platinum-based chemotherapy): median overall survival was 10.2 months with nivolumab vs 6.9 months with placebo (adjusted HR 0.69, 95% CI 0.52 to 0.91, p = 0.0090)
  • IND227 (reviewed phase III trial, previously untreated patients): overall survival was 17.3 months with pembrolizumab plus chemotherapy vs 16.1 months with chemotherapy alone (HR 0.79, 95% CI 0.64 to 0.98, p = 0.0324)
  • BEAT-meso (reviewed phase III trial): adding atezolizumab to bevacizumab and chemotherapy gave no statistically significant difference in overall survival (median 20.5 vs 18.1 months, HR 0.84, 95% CI 0.66 to 1.06, p = 0.14)
  • PROMISE-Meso (reviewed trial, relapsed patients): objective response rate was 22% with pembrolizumab vs 6% with single-agent chemotherapy; there was no difference in the primary end point of progression-free survival
  • Real-world cohort of 119 patients from Australia treated with nivolumab plus ipilimumab: median overall survival was 14.5 months
  • DENIM (reviewed phase II/III trial of dendritic cell vaccination as maintenance after chemotherapy): median overall survival was not statistically different from best supportive care alone (16.8 vs 18.3 months, HR 1.10, 95% CI 0.77 to 1.57, p = 0.62)
  • The authors judged that current evidence does not support using PD-L1 status to select patients for immunotherapy
• The authors' conclusion: The authors concluded that immunotherapy has become a cornerstone of treatment for advanced pleural mesothelioma, particularly the chemotherapy-resistant non-epithelioid subtypes, and that better ways are needed to predict which patients will respond

Topics

Medical terms in this study, explained in our Lexicon: Immunotherapy, Pleural Mesothelioma, Mesothelioma, Prognosis, checkpoint inhibitors, Chemotherapy.

Related studies

• Advances in Immunotherapy of Malignant Pleural Mesothelioma — D. Liao, Y. Yu, et al. (2021)
• Advances in Immunotherapy for Malignant Pleural Mesothelioma: From Emerging Strategies to Translational Insights — R. López-Castro, Á. Fuentes-Martín, et al. (2024)
• Recent Advances in Mesothelioma Treatment: Immunotherapy, Advanced Cell Therapy, and Other Innovative Therapeutic Modalities — R. Suraya, T. Nagano, et al. (2025)
• [Advances in Immunotherapy for Malignant Pleural Mesothelioma] — Y. Chi, Y. Liu, et al. (2022)
• Advances in malignant mesothelioma — B.W. Robinson, R.A. Lake (2005)
• Tumour treating fields therapy for glioblastoma: current advances and future directions — O. Rominiyi, A. Vanderlinden, et al. (2021)

Browse more research in Therapeutic Advances in Medical Oncology, or return to medical research.